Business Wire

SECURE-CODE-WARRIOR

23.7.2024 14:01:30 CEST | Business Wire | Press release

Share
Secure Code Warrior Introduces Industry-first Solution that Measures Developers’ Security Competencies for Code Commits

Secure Code Warrior, the global, developer-driven security leader, today announced the availability of SCW Trust Agent – an industry-first solution that assesses the specific security competencies of developers for every code commit. This innovative offering enables CISOs and application security (AppSec) teams to embrace a Secure-by-Design approach with deeper visibility into their organizations’ software development security posture.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723230392/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SCW Trust Agent provides visibility and control to scale developer driven security (Photo: Business Wire)

The launch of SCW Trust Agent follows the company’s rollout of SCW Trust Score, the first industry benchmark that quantifies the security posture of organizations’ developer teams. Both innovations apply over 20 million learning data points collected from 250,000 developers around the world. These deliver quantitative mechanisms that, when paired with Secure Code Warrior’s agile learning platform, become an integral part of an organization’s secure software development lifecycle.

“At Secure Code Warrior, we are unlocking new value for CISOs by giving them an easy-to-deploy solution to measure the health of code commits and visibility into the hundreds of source code repositories in their organization,” said Pieter Danhieux, Co-founder and CEO, Secure Code Warrior. “Our innovations are putting organizations in a better position to bridge the visibility gap between a developer's skill sets and quality of code produced without sacrificing development velocity.”

SCW Trust Agent works seamlessly with any Git-based code repository including GitHub, GitLab, Atlassian Bitbucket and more. With every commit, it looks to see if the developer making it has the prescribed secure code skillset in the commit’s programming language. It uses this information to give a rating on the health of that commit and aggregates these ratings across all of your repositories.

SCW Trust Agent delivers greater control and flexibility for developer gatekeeping. It allows administrators to set up policies and criteria, ensuring developers meet a baseline set of standards and expectations before developing code. For any gaps in developer skills, they can reference the SCW agile learning platform to upskill their language specific knowledge and competencies.

Overall SCW Trust Agent delivers:

  • Improved Security Controls: Customize policy configuration based on the sensitivity of project requirements
  • Comprehensive Visibility: Actionable insights into the security posture of every commit across all of your code repositories
  • Developer-Led Security at Scale: Deliver projects securely at speed - allowing application security teams to focus on the most sensitive security reviews

For more information on SCW Trust Agent, visit: www.scwtrustagent.com

About Secure Code Warrior

Secure Code Warrior is a secure coding platform that sets the standards that keep our digital world safe. We do this by providing the world’s leading agile learning platform that delivers the most effective secure coding solution for developers to learn, apply, and retain software security principles. More than 600 enterprises trust Secure Code Warrior to implement agile learning security programs and ensure the applications they release are free of vulnerabilities.

For more information about Secure Code Warrior, visit www.securecodewarrior.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723230392/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye